Company Filing History:
Years Active: 2014
Title: Massimo Corsi: Innovator in Histamine H3 Receptor Antagonists
Introduction
Massimo Corsi is a notable inventor based in Florence, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as histamine H3 receptor antagonists. His work is essential in advancing medical treatments and improving patient outcomes.
Latest Patents
Massimo Corsi holds a patent for "Azetidines and cyclobutanes as histamine H3 receptor antagonists." This invention relates to compounds of formula (I), wherein R, R, R, m, n, and X to X have specific meanings as cited in the description and claims. These compounds are useful as histamine H3 receptor antagonists. The invention also encompasses pharmaceutical compositions, the preparation of such compounds, and their production and use as medicaments. He has 1 patent to his name.
Career Highlights
Massimo Corsi is currently associated with Evotec AG, a leading company in drug discovery and development. His role at Evotec AG allows him to leverage his expertise in pharmaceutical innovation and contribute to groundbreaking research.
Collaborations
Throughout his career, Massimo has collaborated with talented individuals such as Adam James Davenport and David James Hallett. These collaborations have further enriched his work and expanded the impact of his inventions.
Conclusion
Massimo Corsi is a distinguished inventor whose work in histamine H3 receptor antagonists has the potential to transform therapeutic approaches in medicine. His contributions to the pharmaceutical industry are invaluable and continue to pave the way for future innovations.